Find out about Professor Mark Lowdell's research on tumour-primed NK cells for acute myeloid leukaemia. Overcoming NK cell resistance in tumours has been a goal of cancer immunotherapists for 30 years. Our patented technology uses a complex of tumour antigens and NK co-stimulatory molecules to prime resting NK cells t kill NK-resistant tumours including AML. These are being tested in clinical trials in the USA at present. The green fluorescence marks a recognition molecule at the synapses. Patients who make an NK immune response to their leukaemia after chemotherapy stay in remission, whereas those who don't relapse within two years. Some patients who were treated with TpNK in a phase 1 trial showed resolution of disease (CTI-03) or prolongation of remission (CTI-01, 04 and 11).